In a tumor model, IL‐15/IL‐15Rα NVs–PD‐1/PD‐L1 inhibitor 1 treatment effectively delayed tumor growth and further enhanced the antitumor response, inhibited tumor growth, and improved the survival rate of mice (Figure 17B–D).[113]. Here, IL15RA is linked to neoplasm.